In studies on early MS, it has been reported that there are no significant differences in CSF GFAP levels between CIS and RRMS, but that GFAP does seem to be a good biomarker for highly active CNS inflammation in patients with CIS and RRMS (32). The gene discussed is GFAP; the disease is in situ carcinoma.